Kidane et al.

1	Deep immune profiling of chronic rhinosinusitis in allergic and
2	non-allergic cohorts using mass cytometry
3	Fana Alem Kidane PhD ¹ , Lena Müller PhD ² , Marianne Rocha-Hasler PhD ¹ , Aldine Tu MSc ¹ ,
4	Victoria Stanek MSc ¹ , Nicholas Campion MD ¹ , Tina Bartosik MD ¹ , Mohammed Zghaebi
5	MSc ¹ , Slagjana Stoshikj MD ³ , Daniela Gompelmann MD ³ , Andreas Spittler MD ² , Marco
6	Idzko MD ³ , Sven Schneider MD ^{1*} , Julia Eckl-Dorna MD, PhD ¹
7	¹ Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
8 9 10 11	² Core Facilities, Medical University of Vienna and Department of Surgery, Research Lab, Vienna, Austria
12 13	³ Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
14 15 16	* Correspondence: Sven Schneider MD Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18- 20, A-1090 Vienna. Email: <u>sven.schneider@meduniwien.ac.at</u>
17	
18	DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
19	SS served as a speaker and/or consultant and/or advisory board member for Sanofi, GSK, and
20	Novartis. SS is an investigator for Novartis and AstraZeneca (grants paid to his institution).
21	JED served as a speaker and/or consultant and/or advisory board member for Sanofi,
22	Allergopharma, AstraZeneca, GSK, and Novartis. JED is an investigator for Novartis and
23	AstraZeneca (grants paid to her institution).
24	
25	
26	
27	

- /
- 28

Kidane et al.

29 ABSTRACT

- 30 Background: Chronic rhinosinusitis (CRS) is characterized by persistent nasal and paranasal
- 31 sinus mucosa inflammation. It comprises two phenotypes, namely CRS with nasal polyps
- 32 (CRSwNP) and without (CRSsNP). CRSwNP can be associated with asthma and
- 33 hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) in a syndrome known as
- 34 NSAID-exacerbated respiratory disease (N-ERD). Furthermore, CRS frequently intertwines
- 35 with respiratory allergies.
- 36 Objective: This study investigated the phenotypic characteristics of peripheral blood
- 37 mononuclear cells (PBMCs) within cohorts of CRS patients, additionally examining the
- influence of comorbid respiratory allergies on these parameters.
- 39 Methods: 24 participants were grouped into controls, CRSsNP, CRSwNP, and N-ERD
- 40 (n=6/group), with half of the patients in each group having respiratory allergies. Levels of
- 41 cytokines were quantified in nasal secretions and sera. The abundance and phenotypic

42 features of immune cells in PBMCs were evaluated through mass cytometry and clustering

- 43 methods.
- 44 Results: N-ERD patients showed heightened type 2 nasal cytokine levels. Mass cytometry
- 45 analysis revealed increased activated naive B cell levels in CRSwNP and N-ERD, while
- 46 resting naive B cells were higher in CRSsNP. Th2a cell levels did not differ between CRS
- 47 subtypes but were significantly elevated in allergic subjects. In CRSwNP and N-ERD

48 patients, naive B cells had a lower CXCR5 and higher CD45RA expression, while NK cells

- 49 displayed reduced CD56 levels.
- 50 Conclusions: There are distinct immunological features in PBMCs of CRS phenotypes and
- allergy, characterized by elevated resting naive B cells in CRSsNP, increased activated naive
- 52 B cells in CRSwNP and N-ERD, and higher Th2a cell levels in allergic subjects.
- 53 Capsule summary: This study examines immunological profiles in different phenotypes of
- 54 CRS with and without comorbid allergy patients, highlighting immune cell intricacies in CRS
- subtypes and immune differences in CRS and respiratory allergy.
- 56 Keywords: Chronic rhinosinusitis, allergy, mass cytometry, nasal cytokines, peripheral blood

57 mononuclear cells, nasal polyps

Kidane et al.

- 59 ABBREVIATIONS
- 60 CCL: Chemokine (C-C Motif) Ligand
- 61 CD: Cluster of differentiation
- 62 CRS: Chronic rhinosinusitis
- 63 CRSsNP: Chronic rhinosinusitis without nasal polyps
- 64 CRSwNP: Chronic rhinosinusitis with nasal polyps
- 65 CyTOF: Cytometry by Time-Of-Flight
- 66 G-CSF: granulocyte-colony stimulating factor
- 67 GM-CSF: Granulocyte-macrophage colony-stimulating factor
- 68 Ig: Immunoglobulin
- 69 IL: Interleukin
- 70 IFN: Interferon
- 71 MMI: Median metal intensity
- 72 NSAIDs: Non-steroidal anti-inflammatory drugs
- 73 N-ERD: NSAIDs-exacerbated respiratory disease
- 74 opt-SNE: Optimized t-distributed stochastic neighbour embedding
- 75 PBMC: Peripheral blood mononuclear cells
- 76 SNOT-20: 20-item sinonasal outcome test
- 77 TNF: Tumour necrosis factor
- 78 TSLP: Thymic stromal lymphopoietin
- 79 VEGF: Vascular endothelial growth factor

80

81

82

Kidane et al.

84 1. INTRODUCTION

85 Chronic rhinosinusitis (CRS) is a complex disease characterized by persistent inflammation of nasal and paranasal sinus mucosa affecting 8-12% of the population ¹. Clinically, CRS is 86 87 classified as CRS with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP), with up 88 to 15% of CRSwNP patients also demonstrating comorbid hypersensitivity to aspirin and 89 other nonsteroidal anti-inflammatory drugs (NSAIDs) as well as asthma in a syndrome called NSAIDs-exacerbated respiratory disease (N-ERD)². CRS is further classified into different 90 endotypes based on inflammatory cell infiltrations and cytokine secretions in nasal tissues³. 91 92 Of these endotypes, the type 2 endotype is predominantly observed in CRSwNP and N-ERD conditions in the Western world ^{2,4-6}. Respiratory allergy, another hallmark type 2 disease, 93 affects up to 30% of the population ⁷.CRS and respiratory allergy involve inflammation in the 94 95 respiratory system and elevated IgE production, but the link between these two conditions is 96 not yet clear⁸.

Numerous previous studies aiming to characterize various immune cell types in CRS and
allergy ⁹⁻¹⁸ employed flow cytometry or immunohistochemistry-based techniques, albeit with
limitations on the number of parameters that could be studied simultaneously. Although
advancements in single-cell parametrization, driven by novel fluorophores and laser systems,
have expanded our understanding of immune cell sub-classes and functional states, spectral
overlap in fluorescence-based cytometry often renders comprehensive immune state analysis
difficult ¹⁹.

104 Mass cytometry, or cytometry by Time-Of-Flight (CyTOF®), offers a potential solution by 105 using heavy-metal isotopes instead of fluorophores, enabling precise quantification of target 106 expression with minimal signal overlap and providing a detailed snapshot of the immune 107 state ¹⁹. Thus, we used this technique to stain 38 immune cell surface markers simultaneously 108 for in-depth immune profiling of peripheral blood mononuclear cells (PBMCs) in CRS 109 patients. This study's primary objective was to analyse alterations in abundance and 110 phenotypic characteristics of PBMCs in cohorts of CRS patients and disease controls. 111 Importantly, each group contained an equal representation of patients with respiratory 112 allergies, allowing us to distinguish whether the changes were exclusively linked to CRS or 113 could be influenced by the allergic predisposition.

Kidane et al.

- 115 2. MATERIAL AND METHODS
- 116 2.1.Study subjects and sample collection

Samples (Serum, nasal secretions, PBMCs) used in this study were taken from the CRS
biobanks of the Department of Otorhinolaryngology, Medical University of Vienna, with the
approval of the Ethical Committee of the Medical University of Vienna (EK Nr. 1492/2023).
The biobanks also contained detailed clinical characteristics of the patients as shown in Table
I and Supplementary Table E1.

122 2.2.Sample preparation

123 Sera, nasal secretions, and PBMCs were prepared following established procedures and are

- 124 outlined in detail in the online repository.
- 125 2.3.IgE measurement

126 Allergen-specific IgE levels were measured in serum using the ALEX® Allergy Explorer

127 assay (Allergy Explorer version 2, MacroArray Diagnostics, Vienna, Austria), encompassing

128 over 280 allergen extracts and molecular allergens according to the manufacturer's

129 instructions, which is briefly summarized in the online repository. A description of the main

130 respiratory allergens used to determine a patient's allergic status in Fig. 1 of this manuscript

- is also provided in Supplementary Table E2.
- 132 *2.4.Cytokine measurements*

133 Thirty-three cytokines were analysed in nasal secretions and sera for using the Meso Scale

134 Discovery (MSD) multiplex U-Plex platform (MSD, Rockville, MA, USA) as described

- 135 before 20 , and as outlined in the online repository.
- 136 2.5.Mass Cytometry: Staining and acquisition of PBMCs using MaxPAR®
 137 Immunoprofiling Assay and CyToF

138 Before immunostaining PBMCs, the frozen cells underwent a careful thawing process, as

139 described in the online repository. For immunostaining, the PBMCs were subjected to the

- 140 MaxPAR Direct Immunoprofiling Assay (Standard BioTools, South San Francisco, CA,
- 141 USA) supplemented with commercial and in-house labeled antibodies given in

142 Supplementary Table E3 following the manufacturer's instructions. A brief description of the

staining and acquisition procedure can be found in the online repository. A detailed protocol

144 has been described elsewhere 21 .

Kidane et al.

145 2.6.Processing of Mass Cytometry Data Using Dimensionality Reduction and 146 FlowSOM

A step-wise approach was followed for analysis: normalized raw data files were imported
into Cytobank (Beckman Coulter, Brea, CA, USA), and then quality control was employed to
remove undesired events (dead cells, debris, normalization beads, aggregates, and coincident
ion clouds) by manually gating out beads and according to residual, center, offset, width,

151 event length, and DNA intercalator signals in biaxial plots vs Time parameter using Gaussian

152 discrimination, leaving viable cell events for downstream analysis.

153 After data clean-up, dimensionality reduction was performed using opt-SNE in Cytobank on

154 gated live cells using 38 channels (refer to Supplementary Table E3) with the advanced

settings left on the software's default.

156 The opt-SNE was then visually inspected to identify distinctive clusters. Then, FlowSOM

157 clustering was performed on Cytobank (Beckman Coulter) utilizing the opt-SNE-reduced

data as input. All the channels used for opt-SNE were also implemented in the FlowSOM

analysis. Subsequently, clusters were further annotated based on characteristic marker

160 expression patterns. Cell population/cluster percentage data across different groups and

161 markers' median metal intensity (MMI) were exported to GraphPad prism (GraphPad

162 Software, Boston, MA, USA) for a statistical analysis and graph output. Further information

163 on opt-SNE and FlowSOM algorithm settings can be found on Cytobank's platform

164 (cytobank.org).

165

2.7. Statistical Analysis

All statistical analyses were conducted using GraphPad Prism 9.5.1(GraphPad Software).

167 Cytokine values underwent a log transformation. Hierarchical clustering analysis of levels of

168 cytokines and immune cell populations was performed using a heat-mapper with Spearman

169 Rank Correlation as a distance measurement method 22 . Furthermore, data on the percentage

170 of cell populations and marker expression were retrieved from Cytobank and subsequently

171 imported into GraphPad Prism for comprehensive analysis.

172 Given the nature of the data distribution, non-parametric tests were employed for group

173 comparisons. Specifically, the Mann-Whitney U test was utilized to evaluate differences

between allergic and non-allergic individuals. To assess distinctions among the CRSsNP,

175 CRSwNP, and N-ERD groups, the Kruskal-Wallis test was applied along with Dunn's test for

Kidane et al.

- multiple comparisons. For all analyses, a significance level of p < 0.05 was established as the
- 177 threshold for statistical significance.

Kidane et al.

179 2. RESULTS

180 *3.1.Subject characteristics*

181	Demographic and clinical characteristics of the study cohorts are given in Table I. A total of
182	24 participants grouped into subjects without any signs of acute or chronic nasal
183	inflammation=Controls (n=6), CRSsNP (n=6), CRSwNP (n=6) and N-ERD (n=6) were
184	included in the study. Half of the cohorts in each group were known to have a respiratory
185	allergy ($n=3$ per group) or were not allergic ($n=3$ per group). An individual overview of the
186	patient characteristics is provided in Supplementary Table E1.
187	3.2.Immunological profiling of allergic and non-allergic cohorts based on allergen-
188	specific IgE and cytokine levels
189	Participants were categorised as allergic or non-allergic based on their clinical history and
190	allergen-specific positive Skin Prick Test reaction or specific serum IgE levels by ALEX2
191	microarray. As shown in Fig. 1A, all patients (except two individuals with positive skin prick
192	test only) classified as allergic based on their clinical history showed detectable (≥ 0.35
193	kUA/L) specific serum IgE levels to at least one respiratory allergen.
194	Levels of 33 cytokines measured both in nasal secretions and serum showed no significant
195	differences between allergic and non-allergic subjects (data not shown); exemplary type 2
196	cytokine levels are given for nasal secretions (Fig. 1B) and serum (Fig. 1C).
197	3.3. Cytokine profiling reveals distinct inflammatory patterns in nasal secretions of N-
198	ERD, CRSsNP, and CRSwNP patients
199	To determine differences in cytokine patterns in patients suffering from various CRS disease
200	entities compared to disease controls, hierarchical clustering analysis of cytokine levels in
201	nasal secretion (Fig. 2A) and serum (Fig. 2B) was performed. In nasal secretions, we found a
202	clustering of type 2 associated cytokines CCL17, Eotaxin, Eotaxin-3, IL-5 and IL-13, which
203	were highly upregulated in N-ERD patients but also elevated in CRSwNP patients. Individual
204	cytokine analysis confirmed that N-ERD patients showed significantly elevated levels of IL-5
205	compared to the Control ($p=0.0423$) and CRSsNP ($p=0.0423$) groups. Similarly, there were
206	significantly higher levels of IL-9 (p=0.0018), CCL17 (p=0.0225), Eotaxin (0.0076), and
207	Eotaxin-3 ($p=0.0049$) in N-ERD patients in comparison to CRSsNP (Fig.2C). In contrast to
208	nasal secretions, no significant differences in cytokine levels were observed in sera of the
209	patients between groups (Fig. 2D).

Kidane et al.

- 210 3.4. High-resolution immune profiling by mass cytometry reveals significantly higher 211 numbers of Th2a cells in the blood of allergic subjects but not of patients suffering from CRS
- 212

213 To get an insight into the immune cell subsets associated with CRS as well as allergic 214 diseases, high-resolution immune profiling was conducted in PBMCs of the participants 215 (n=22) by mass cytometry. Two patients in the CRSwNP allergic group were excluded from 216 the analysis due to insufficient cell numbers for in-depth analysis. Mass cytometry data, 217 coupled with dimensionality reduction techniques (Fig. 3A) and unbiased automated 218 clustering analyses by FlowSOM, was conducted and showed clear separation of cell 219 populations based on canonical markers as exemplified in Fig. 3A. As shown in Fig. 3B and 220 Fig. 3C clusters of immune cells, encompassing natural killer (NK), natural killer T (NKT), 221 mucosal-associated invariant T (MAIT), CD4+ T (CD4 T), Regulatory T (T-reg), CD8+ T 222 (CD8 T), Gamma-Delta T ($\gamma\delta$ T), Memory B (Memory B), Naive B (Naive B), Plasmablasts 223 (Plasmas), Monocytes, myeloid Dendritic cells (mDCs), and plasmacytoid Dendritic cells 224 (pDCs) in the different disease entities. Differential abundance analysis to quantify immune 225 cell subpopulations revealed only a slight trend towards increased levels of T-reg and Th2 226 cells in the PBMCs of CRSsNP and N-ERD patients (Supplementary Fig. E1). No significant 227 alterations in the other cell types were identified between the disease groups (Fig. 3D). 228 As Th2a cells have previously been described to be elevated in the blood of allergic subjects²³, we next investigated if they were also elevated in CRS subtypes with strong type 2 229 230 profile. To that aim, we manually gated the subpopulation of Th2a cells based on established surface marker expression (CD27⁻CD45RB⁻CD161⁺ CRTH2/CD294⁺CD49d⁺²⁴) within 231 232 PBMCs (Fig. 3E). Despite being a relatively small fraction of the total PBMC population, the 233 Th2a immune cell subset exhibited a notable increase in allergic individuals (p=0.0133). 234 Intriguingly, when comparing these cells within the CRS groups, no significant changes were 235 observed (p=0.7650) (Fig. 3E). As shown in Supplementary Fig. E2, no differences were 236 seen when CRS and allergy status stratified the data.

237

3.5. Comprehensive profiling of B cell subpopulations using FlowSOM analysis

238 Given the pivotal role of B cells in the pathophysiology of both CRS and allergic conditions,

239 we conducted an extensive analysis of B cell populations (Fig. 4) within PBMCs. This

- 240 analysis was performed using an automated assessment of marker expression profiles via
- 241 FlowSOM leading to identification of ten distinct B-cell metaclusters (B1-B10) (Fig. 4A).

Kidane et al.

- 242 Notably, several markers, including CD45RB, CCR6, CD11c, CD27, CXCR5, CD38,
- 243 CD49d, HLA-DR, CD11b, and CD20 exhibited differential expression within the B cell
- 244 population, giving rise to these uniquely defined metaclusters (Fig. 4B).
- Broadly, the metaclusters consisted of naive B cells, characterized by CD27⁻ (Fig. 4B)
- 246 (specifically B1, B2, B3, B7 & B10), and memory B cells, characterized by CD27⁺
- 247 (including B4, B5, B6, B8 & B9), among which B4 and B9 displayed high CD38⁺ expression
- and thus are putative plasmablasts. As illustrated in Fig. 4C-F, the metaclusters were
- 249 differently sized, with B1, a naïve B cell metacluster, constituting approximately 60% of the
- total B cell population in control subjects. In contrast, B7, another type of naïve B cell
- distinguished by CD11b surface marker, accounted for just 0.4% of the B cell population in
- control subjects.

253 To investigate potential differences, we conducted an abundance analysis of the identified B

254 cell metaclusters across various groups: Control, CRSsNP, CRSwNP, and N-ERD, as well as

allergic and non-allergic subjects (Fig. 4C-F). Notably, metaclusters B1 and B2 (representing

naïve B cells marked by higher expression of CCR6 and CXCR5) showed a trend towards

257 increased levels in CRSsNP patients, which reached statistical significance for B1 cells as

- compared to N-ERD patients (*p*=0.0231). Conversely, N-ERD and CRSwNP groups showed
- a significantly increased frequency of B3 (naïve B cell with low expression of CCR6)

compared to CRSsNP (N-ERD-CRSsNP: p=0.0141, CRSwNP-CRSsNP: p=0.0266) (Fig.

261 4C).

A more in-depth analysis of the abundance in the context of allergy (Fig. 4D-F;

263 Supplementary Fig. E3) revealed that B3 was not increased in allergic subjects, indicating

- that the observed increase in the naïve B1, B2, and B3 frequency was solely due to the
- underlying CRS disease. Allergic subjects, however, had a decreased frequency of memory
- 266 B-cell metaclusters B4 (p=0.0169), B6 (p=0.0206), B9 (p=0.0426), and naïve B cell

267 metacluster B10 (p=0.0249), as compared to non-allergic subjects.

- 3.6.Immunophenotypic distinctions in B cell subtypes illuminate unique features of N ERD derived B cells
- 270 We further analysed surface marker expression levels in B cell metaclusters of the three CRS

disease groups. N-ERD and CRSsNP patients showed a trend towards elevated median metal

272 intensity (MMI) levels of the differentiation marker CD45RA across all B cell metaclusters,

which reached a significant difference in B10 of CRSsNP compared to Control (p=0.0082).

Kidane et al.

274	Conversely, N-ERD patients displayed decreased levels of CXCR5 expression in all B cell				
275	metaclusters B1 to B10 when compared to Control, CRSsNP, and CRSwNP groups (Fig. 5B),				
276	yet differences were not statistically significant (p >0.05). Similarly, N-ERD patients				
277	exhibited a significantly decreased expression of CD49d ($p=0.0402$) in B9 metacluster				
278	relative to the Control (Fig. 5B). Overall, these findings highlight distinct immunophenotypic				
279	changes in B cell subtypes in N-ERD patients, characterized by elevated CD45RA expression				
280	and reduced levels of CXCR5 and CD49d.				
281	Furthermore, we analysed the MMI in B cell metaclusters in allergic and non-allergic				
282	individuals. The expression levels were comparable between the two groups across most B				
283	cell metaclusters, except for B7, where expression levels of CD49d were significantly higher				
284	in non-allergic as compared to allergic patients ($p=0.0138$) (Supplementary Fig. E4).				
285	3.7. Heterogeneity in Natural Killer (NK) Cell Populations in CRSsNP, N-ERD, and				
286	allergic individuals				
287	Another focus of this study was exploring the heterogeneity of Natural Killer (NK) cell				
288	populations in the study cohorts as NK cell dysfunction has previously been reported in CRS				
289	²⁵ . The NK metaclusters were characterized based on their surface marker expression profiles				
290	(Fig. 6A and B). They revealed four distinct NK metaclusters, Late-stage (LS) NK1, LS				
291	NK2, Early-stage (ES) NK1, and ES NK2, in the PBMCs. While no significant differences in				
292	abundance were observed between the CRSsNP, CRSwNP, N-ERD, and Control (p >0.05)				
293	(Fig. 6C), an increased frequency of LS NK2 cells was noted in non-allergic individuals				
294	compared to allergic individuals (p =0.0215). Additionally, expression levels of CD45RA and				
295	CD56 within different NK metaclusters exhibited variations in the context of CRSsNP,				
296	CRSwNP, and N-ERD (Fig. 6E). Overall, both CRSsNP and N-ERD groups demonstrated				
297	elevated levels of CD45RA across all metaclusters, with LS NK1 exhibiting a statistically				
298	significant increase in CRSsNP versus control ($p=0.0306$). Similarly, CRSsNP groups				
299	showed an elevated level of median CD56 intensity, which showed significant differences in				
300	ES NK 1 cells compared to CRSwNP patients ($p=0.0323$).				

301

Kidane et al.

303 4. DISCUSSION

Here, we conducted a detailed analysis of immune cell profiles in PBMCs of patients

suffering from various forms of CRS: CRSsNP, CRSwNP, and N-ERD, with a further

306 distinction in patients with and without respiratory allergies.

307 Using a panel comprising 33 different cytokines, we found elevated concentrations of type 2-

associated cytokines, including CCL17, Eotaxin, Eotaxin-3, IL-5, and IL-9, in nasal

secretions of CRSwNP patients with the highest levels observed in N-ERD patients. This

agrees with earlier reports of CRSwNP and especially N-ERD being dominated by type 2-

driven inflammatory conditions in the Western world ^{2,4-6}. CRSsNP patients showed a more

312 mixed pattern of type 1 and type 3 endotypes and strong inter-individual differences in

313 accordance with previous reports $^{2,4-6}$.

314 Our main objective in this study was to investigate differences in levels and characteristics of

various immune cell types within CRS using mass cytometry. With regards to T cell

subpopulations, we detected no significant differences in peripheral blood. Though mass

317 cytometry has recently revealed differences in nasal polyp-derived T cell subsets with a

higher percentage of CD161^{hi} CXCR3^{lo} expressing T helper cells in nasal polyps as

319 compared to control tissues ²⁶, we only detected a trend towards elevated Th2 cell levels in

320 blood of CRSwNP patients and N-ERD patients, which did not reach significance. The lack

of difference in Th2 cell numbers between different patient groups has also been observed

322 using flow cytometry approaches 27 .

323 To the best of our knowledge, we are the first to identify Th2a cells based on the expression

of CRTH2, CD161, CD49d and CD27 in the blood of patients using mass cytometry. This

325 Th2 subset was initially described by Wambre et al as associated with allergic disease status

²³ and recently put forward as a candidate for monitoring success during immunotherapy for

food 28 or respiratory allergens 29 . Interestingly, we found no differences in Th2a levels

between CRS entities but significantly increased levels in allergic versus non-allergic patients

329 regardless of their CRS status. Our observation that allergic patients had significantly

elevated levels of Th2a cells despite being a heterogeneous group with various levels of

331 specific IgE against different allergen sources, from tree to animal, implicates Th2a levels as

a potentially universal biomarker and therapeutic target for allergic disease 30 .

Eosinophils have long been regarded as main drivers of CRSwNP. However, with the

introduction and success of anti-IgE and anti-ILA/IL-13 antibodies in treating severe disease

Kidane et al.

³¹, B cells have also been attributed to an important role in pathogenesis ^{32, 33}. In this line, it 335 336 has been shown that chronic airway inflammation creates an environment well-suited for B cell differentiation ³⁴ and that the nasal mucosa of CRS shows elevated levels of naïve B 337 338 cells, memory B cells and plasma cells, with the highest number observed in CRSwNP patients ^{35,36}. In the blood of CRS patients, we did not observe differences in major B cell 339 subsets, which is in agreement with previous data ³⁵. Thus, we performed a deeper 340 341 characterization employing an unsupervised high-resolution profiling approach using 342 FlowSOM. This enabled us to distinguish ten distinct B cells subtypes based on the 343 expression of phenotypic markers, including CD45RB, CD27, CXCR5, CD38, CD49d, HLA-344 DR, CD19, and CD20. Though not significant, we observed in CRSsNP patients a trend 345 towards elevated levels of B1 and B2 metaclusters, which show characteristics of resting naïve B cells (CD27⁻CD38⁺IgD⁺)³⁷. N-ERD patients, on the other hand, displayed a 346 347 significantly increased frequency of B3, another subset of naive B cells characterized by the 348 absence of CD27 and CD38 expression but positive for IgD. These cells can be identified as putative "mature-naive" ³⁸ or "activated naïve" ³⁷ B cells. Additionally, B-cells of CRS 349 350 patients showed a trend towards reduced levels of the chemokine receptor CXCR5 and the 351 integrin CD49d in selected metaclusters, which are both involved in establishing and maintaining optimal germinal center reactions^{39,40}. These findings are interesting in light of 352 353 previous observations that IgE-secreting cells from nasal polyps are mainly guided to extrafollicular pathways ^{34,41}. In summary, it is compelling to speculate that blood-borne 354 355 activated naïve B cells, enriched in N-ERD patients, may migrate to extrafollicular structures 356 within the nasal polyp, where they may further differentiate into antibody-producing cells 33 . NK cell dysfunction has also been observed in CRS patients with decreased effector function 357 being associated with increased eosinophilic inflammation 42 and disease severeness 43 . In 358 this context, we observed reduced expression of the phenotypic NK cell activation marker 359 CD56^{44,45} in CRSwNP patients. As CD56-negative NK cell subsets are enriched in patients 360 with chronic virus infections 46,47 , it is conceivable that the loss of CD56 observed in our 361

study could be at least partly driven by the repeated infections in the course of CRS.

In patients suffering from respiratory allergies, we observed significantly reduced levels of late-stage NK cells expressing CD16 regardless of their allergic status. However, there were no differences in the CD56⁺CD16⁻ subsets as previously described in peanut-allergic subjects ⁴⁸ or subjects suffering from atopic dermatitis ⁴⁹. Our differential results could be both due to

Kidane et al.

- the different routes of allergen sensitization or due to the absence of allergen restimulation in
- 368 our experimental design as compared to Zhou et al.⁴⁸
- 369 Limitations of our study include the relatively small sample size with regard to different CRS
- subtypes and the absence of nasal mucosa samples. It could also be that the often discussed
- lower sensitivity of mass cytometry 50 as compared to flow cytometry may have had an
- impact on our results. However, a recent report showed the comparability between the two
- techniques with regard to T cell subsets 26 .
- 374 In conclusion, this study provided a comprehensive analysis of blood-derived immune cell
- profiles in various forms of CRS and allergic patients. Notably, an increased presence of
- Th2a cells, pivotal in allergic responses, was observed in allergic cohorts. Further, our
- analysis of B and NK cell populations identified distinct subtypes with potential implications
- for both type 2 diseases. These findings contribute to a deeper understanding of the
- immunological profiles in PBMCs of patients with CRS or allergy, shedding light on
- 380 potential avenues for further research and therapeutic approaches.
- 381
- 382
- 383
- 384
- 385
- 386
- 387
- 388
- 389
- 390
- 391

Kidane et al.

392 5. REFERENCES

393	1.	Fokkens, W.J., Lund, V.J., Hopkins, C., Hellings, P.W., Kern, R., Reitsma, S., Toppila-Salmi, S.,
394		Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020). European Position Paper on
395		Rhinosinusitis and Nasal Polyps 2020.
396	2.	Kato, A., Peters, A.T., Stevens, W.W., Schleimer, R.P., Tan, B.K., and Kern, R.C. (2022).
397		Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis,
398		clinical findings, and treatment approaches. Allergy 77, 812-826. 10.1111/all.15074.
399	3.	Liao, B., Liu, J.X., Li, Z.Y., Zhen, Z., Cao, P.P., Yao, Y., Long, X.B., Wang, H., Wang, Y.,
400		Schleimer, R., and Liu, Z. (2018). Multidimensional endotypes of chronic rhinosinusitis and
401		their association with treatment outcomes. Allergy 73, 1459-1469. 10.1111/all.13411.
402	4.	Tomassen, P., Vandeplas, G., Van Zele, T., Cardell, LO., Arebro, J., Olze, H., Förster-
403		Ruhrmann, U., Kowalski, M.L., Olszewska-Ziąber, A., Holtappels, G., et al. (2016).
404		Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.
405	5.	Wang, X., Zhang, N., Bo, M., Holtappels, G., Zheng, M., Lou, H., Wang, H., Zhang, L., and
406		Bachert, C. (2016). Diversity of T(H) cytokine profiles in patients with chronic rhinosinusitis: A
407		multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol 138, 1344-1353.
408		10.1016/j.jaci.2016.05.041.
409	6.	Tan, B.K., Klingler, A.I., Poposki, J.A., Stevens, W.W., Peters, A.T., Suh, L.A., Norton, J., Carter,
410		R.G., Hulse, K.E., Harris, K.E., et al. (2017). Heterogeneous inflammatory patterns in chronic
411		rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol 139, 699-703
412		e697. 10.1016/j.jaci.2016.06.063.
413	7.	Valenta, R., Karaulov, A., Niederberger, V., Gattinger, P., van Hage, M., Flicker, S., Linhart, B.,
414		Campana, R., Focke-Tejkl, M., Curin, M., et al. (2018). Molecular Aspects of Allergens and
415		Allergy. Adv Immunol <i>138,</i> 195-256. 10.1016/bs.ai.2018.03.002.
416	8.	Marcus, S., DelGaudio, J.M., Roland, L.T., and Wise, S.K. (2019). Chronic Rhinosinusitis: Does
417		Allergy Play a Role? Med Sci (Basel) 7. 10.3390/medsci7020030.
418	9.	Agache, I., Rocha, C., Beltran, J., Song, Y., Posso, M., Sola, I., Alonso-Coello, P., Akdis, C.,
419		Akdis, M., Canonica, W., et al. (2020). Efficacy and safety of treatment with biologicals
420		(benralizumab, dupilumab and omalizumab) for severe allergic asthma. Allergy.
421		10.1111/all.14235.
422	10.	Eckl-Dorna, J., Pree, I., Reisinger, J., Marth, K., Chen, K.W., Vrtala, S., Spitzauer, S., Valenta,
423		R., and Niederberger, V. (2012). The majority of allergen-specific IgE in the blood of allergic
424		patients does not originate from blood-derived B cells or plasma cells. Clin Exp Allergy 42,
425		1347-1355. 10.1111/j.1365-2222.2012.04030.x.
426	11.	Wachholz, P.A., Nouri-Aria, K.T., Wilson, D.R., Walker, S.M., Verhoef, A., Till, S.J., and
427		Durham, S.R. (2002). Grass pollen immunotherapy for hayfever is associated with increases
428		in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 105, 56-62.
429	12.	Sharma, S., Watanabe, S., Sivam, A., Wang, J., Neuwirth, S.J., Perez, R.I., De Tineo, M.,
430		Baroody, F.M., Naclerio, R.M., and Pinto, J.M. (2012). Peripheral blood and tissue T
431		regulatory cells in chronic rhinosinusitis. Am J Rhinol Allergy 26, 371-379.
432	_	10.2500/ajra.2012.26.3800.
433	13.	Tsuda, T., Suzuki, M., Kato, Y., Kidoguchi, M., Kumai, T., Fujieda, S., and Sakashita, M. (2023).
434		The current findings in eosinophilic chronic rhinosinusitis. Auris Nasus Larynx.
435		10.1016/j.anl.2023.08.002.
436	14.	Delemarre, T., and Bachert, C. (2023). Neutrophilic inflammation in chronic rhinosinusitis.
437		Curr Opin Allergy Clin Immunol 23, 14-21. 10.1097/ACI.000000000000868.
438	15.	Kato, A., Schleimer, R.P., and Bleier, B.S. (2022). Mechanisms and pathogenesis of chronic
439		rhinosinusitis. J Allergy Clin Immunol <i>149</i> , 1491-1503. 10.1016/j.jaci.2022.02.016.
440	16.	Shamji, M.H., Bellido, V., Scadding, G.W., Layhadi, J.A., Cheung, D.K., Calderon, M.A., Asare,
441		A., Gao, Z., Turka, L.A., Tchao, N., et al. (2015). Effector cell signature in peripheral blood

Kidane et al.

442		following nasal allergen challenge in grass pollen allergic individuals. Allergy <i>70</i> , 171-179.
443	. –	10.1111/all.12543.
444	17.	Ickrath, P., Kleinsasser, N., Ding, X., Ginzkey, C., Beyersdorf, N., Hagen, R., Kerkau, T., and
445		Hackenberg, S. (2017). Characterization of 1-cell subpopulations in patients with chronic
446		rninosinusitis with hasal polyposis. Allergy Rhinol (Providence) 8, 139-147.
447	10	10.2500/df.2017.8.0214. Milikavia D. Bassiauni A. Caakalay C. Ou I. Hauban F. Warmald B.L. and Vraugda S.
440 110	10.	(2014) Association between group 2 inpate lymphoid cells enrichment, pasel polyes and
4450		allergy in chronic rhiposinusitis. Allergy 69, 1154-1161, 10, 1111/all 12440
450	19	Hartmann, E.L. and Bendall, S.C. (2020). Immune monitoring using mass cytometry and
452	15.	related high-dimensional imaging approaches. Nat Rev Rheumatol 16, 87-99
453		10 1038/s41584-019-0338-z
454	20.	Schneider, S., Poglitsch, K., Morgenstern, C., Quint, T., Gangl, K., Sinz, C., Bartosik, T.,
455		Campion, N.J., Liu, D.T., Landegger, L.D., et al. (2023). Dupilumab increases aspirin tolerance
456		in NSAID-exacerbated respiratory disease. Eur Respir J 61, 10,1183/13993003,01335-2022.
457	21.	Rocha-Hasler, M., Muller, L., Wagner, A., Tu, A., Stanek, V., Campion, N.J., Bartosik, T.,
458		Zghaebi, M., Stoshikj, S., Gompelmann, D., et al. (2022). Using mass cytometry for the
459		analysis of samples of the human airways. Front Immunol 13, 1004583.
460		10.3389/fimmu.2022.1004583.
461	22.	Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J.R., Maciejewski, A., and Wishart, D.S.
462		(2016). Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res 44, W147-153.
463		10.1093/nar/gkw419.
464	23.	Wambre, E.R.G., DeLong, J.H., James, E.A., Robinson, D., and Kwok, W.W. (2012). TH2A Cells
465		As a Unique TH2 Cell Subset in Allergic Individuals: Steps Toward a T Cell Biomarker For
466		Allergy.
467	24.	Wambre, E., Bajzik, V., DeLong, J.H., O'Brien, K., Nguyen, Q.A., Speake, C., Gersuk, V.H.,
468		DeBerg, H.A., Whalen, E., Ni, C., et al. (2017). A phenotypically and functionally distinct
469		human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med 9.
470	25	10.1126/scitransimed.aam91/1.
471	25.	Kaczmarek, M., Wasicka, K., Tin-Tsen Chou, J., Popowicz, P., Kzetelska, Z., Lagiedo-
472		chronic rhinosinusitis show docroased maturity and limited expression of functional
475		recentors Immunohiology 225 151890 10 1016/i imbio 2019 11 025
474	26	Bartemes K.B. Chohy G. O'Brien E.K. Stokken J.K. Bayelko K.D. and Kita H. (2021). Mass
476	20.	cytometry reveals unique subsets of T cells and lymphoid cells in pasal polyps from patients
477		with chronic rhinosinusitis (CRS) Allergy 76, 2222-2226, 10, 1111/all 14720
478	27.	Polasky, C., Loval, K., Idel, C., Wetterauer, D., Heidemann, M., Bruchhage, K.L., and Pries, R.
479		(2021). Alteration of blood monocyte subsets in chronic rhinosinusitis with regard to anti-
480		inflammatory 1,8-Cineol treatment. Rhinology Online 4, 194-202. 10.4193/rhinol/21.032.
481	28.	Hardy, L.C., Smeekens, J.M., and Kulis, M.D. (2019). Biomarkers in Food Allergy
482		Immunotherapy. Curr Allergy Asthma Rep <i>19</i> , 61. 10.1007/s11882-019-0894-y.
483	29.	Luce, S., Batard, T., Bordas-Le Floch, V., Le Gall, M., and Mascarell, L. (2021). Decrease in
484		CD38(+) TH2A cell frequencies following immunotherapy with house dust mite tablet
485		correlates with humoral responses. Clin Exp Allergy <i>51</i> , 1057-1068. 10.1111/cea.13891.
486	30.	Huang, Z., Chu, M., Chen, X., Wang, Z., Jiang, L., Ma, Y., and Wang, Y. (2022). Th2A cells: The
487		pathogenic players in allergic diseases. Front Immunol 13, 916778.
488		10.3389/fimmu.2022.916778.
489	31.	Striz, I., Golebski, K., Strizova, Z., Loukides, S., Bakakos, P., Hanania, N.A., Jesenak, M., and
490		Diamant, Z. (2023). New insights into the pathophysiology and therapeutic targets of asthma
491		and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond) 137, 727-
492		/53.10.1042/C520190281.

Kidane et al.

493 494	32.	Kariyawasam, H.H., and James, L.K. (2021). Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps? Lancet Respir Med <i>9</i> . e97, 10.1016/S2213-2600(21)00223-
495		Χ.
496	33.	Buchheit, K.M., Dwver, D.F., Ordovas-Montanes, J., Katz, H.R., Lewis, E., Vukovic, M., Lai, J.,
497		Bankova, L.G., Bhattacharvva, N., Shalek, A.K., et al. (2020), IL-5Ralpha marks nasal polyp
498		IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin
499		Immunol 145, 1574-1584, 10.1016/i.jaci.2020.02.035,
500	34.	Feldman, S., Kasjanski, R., Poposki, J., Hernandez, D., Chen, J.N., Norton, J.E., Suh, L., Carter,
501		R.G., Stevens, W.W., Peters, A.T., et al. (2017). Chronic airway inflammation provides a
502		unique environment for B cell activation and antibody production. Clin Exp Allergy 47, 457-
503		466. 10.1111/cea.12878.
504	35.	Psaltis, A.J., Schlosser, R.J., Yawn, J.R., Henriquez, O., and Mulligan, J.K. (2013).
505		Characterization of B-cell subpopulations in patients with chronic rhinosinusitis. Int Forum
506		Allergy Rhinol 3, 621-629. 10.1002/alr.21173.
507	36.	Miljkovic, D., Psaltis, A., Wormald, P.J., and Vreugde, S. (2018). Naive and effector B-cell
508		subtypes are increased in chronic rhinosinusitis with polyps. Am J Rhinol Allergy 32, 3-6.
509		10.2500/ajra.2018.32.4496.
510	37.	Satitsuksanoa, P., Iwasaki, S., Boersma, J., Imam, M.B., Schneider, S.R., Chang, I., van de
511		Veen, W., and Akdis, M. (2023). B cells: The many facets of B cells in allergic diseases. J
512		Allergy Clin Immunol 152, 567-581. 10.1016/j.jaci.2023.05.011.
513	38.	Kaminski, D.A., Wei, C., Qian, Y., Rosenberg, A.F., and Sanz, I. (2012). Advances in human B
514		cell phenotypic profiling. Front Immunol <i>3</i> , 302. 10.3389/fimmu.2012.00302.
515	39.	Wu, B.X., Zhao, L.D., and Zhang, X. (2019). CXCR4 and CXCR5 orchestrate dynamic germinal
516		center reactions and may contribute to the pathogenesis of systemic lupus erythematosus.
517		Cell Mol Immunol <i>16</i> , 724-726. 10.1038/s41423-019-0244-y.
518	40.	Yoon, S.O., Lee, I.Y., Zhang, X., Zapata, M.C., and Choi, Y.S. (2014). CD9 may contribute to the
519		survival of human germinal center B cells by facilitating the interaction with follicular
520		dendritic cells. FEBS Open Bio 4, 370-376. 10.1016/j.fob.2014.04.001.
521	41.	Corrado, A., Ramonell, R.P., Woodruff, M.C., Tipton, C., Wise, S., Levy, J., DelGaudio, J.,
522		Kuruvilla, M.E., Magliocca, K.R., Tomar, D., et al. (2021). Extrafollicular IgD+ B cells generate
523		IgE antibody secreting cells in the nasal mucosa. Mucosal Immunol 14, 1144-1159.
524	42	10.1038/s41385-021-00410-w.
525	42.	Kim, J.H., Choi, G.E., Lee, B.J., Kwon, S.W., Lee, S.H., Kim, H.S., and Jang, Y.J. (2016). Natural
526		killer cells regulate eosinophilic inflammation in chronic rhinosinusitis. Sci Rep 6, 2/615.
527	40	10.1038/srep27615.
528	43.	KIM, J.H., KIM, G.E., CNO, G.S., KWON, H.J., JOO, C.H., KIM, H.S., and Jang, Y.J. (2013). Natural
520		One 8 e77177 10 1271 /journal none 0077177
530	44	Van Acker H.H. Cansomidis A. Smits E.L. and Van Tendeloo, V.E. (2017) CD56 in the
532	44.	Immune System: More Than a Marker for Cytotoxicity? Front Immunol & 892
533		10 3389/fimmu 2017 00892
534	45	Vukicevic M. Chalandon V. Helg C. Matthes T. Dantin C. Huard B. Chizzolini C.
535	45.	Passweg L and Roosnek F (2010) CD56bright NK cells after hematopoietic stem cell
536		transplantation are activated mature NK cells that expand in patients with low numbers of T
537		cells. Eur J Immunol 40. 3246-3254. 10.1002/eii.200940016.
538	46.	Biorkstrom, N.K., Liunggren, H.G., and Sandberg, J.K. (2010). CD56 negative NK cells: origin.
539		function, and role in chronic viral disease. Trends Immunol 31, 401-406.
540		10.1016/j.it.2010.08.003.
541	47.	Domenico Mavilio, G.L., Janet Benjamin, Diana Kim, Dean Follman, Emanuela Marcenaro, M.
542		Angeline O'Shea, Audrey Kinter, Colin Kovacs, Alessandro Moretta, Anthony S. Fauci
543		Characterization of CD56–/CD16+natural killer (NK) cells: A highly dysfunctional NK subset

Kidane et al.

544		expanded in HIV-infected viremic individuals. Proceedings of the National Academy of
545		Sciences <i>102</i> , 2886-2891.
546	48.	Zhou, X., Yu, W., Dunham, D.M., Schuetz, J.P., Blish, C.A., DeKruyff, R.H., and Nadeau, K.C.
547		(2022). Cytometric analysis reveals an association between allergen-responsive natural killer
548		cells and human peanut allergy. J Clin Invest 132. 10.1172/JCI157962.
549	49.	Carbone, T., Nasorri, F., Pennino, D., Eyerich, K., Foerster, S., Cifaldi, L., Traidl-Hoffman, C.,
550		Behrendt, H., and Cavani, A. (2010). CD56highCD16-CD62L- NK cells accumulate in allergic
551		contact dermatitis and contribute to the expression of allergic responses. J Immunol 184,
552		1102-1110. 10.4049/jimmunol.0902518.
553	50.	Spitzer, Matthew H., and Nolan, Garry P. (2016). Mass Cytometry: Single Cells, Many
554		Features.
FFF		
222		

Kidane et al.

6. ACKNOWLEDGMENT

- We would like to thank the technical teams of Standard BioTools and Cytobank for their
- support during the study.

7. TABLES

Table I: Patient characteristics of study cohorts

Group *	Control	CRSsNP	CRSwNP	N-ERD	<i>P</i> value
No of subjects	6	6	6	6	n.a
Sex, M/F	2/4	4/2	4/2	5/1	n.a
Median age in years (range)	40 (24) ⁺	38 (33)	49 (34)	54 (22)	0.0788
Median TPS ^{**} (range)	0 (0)	0 (0)	4 (6)	5.5 (5)	0.0002
Median SNOT-20 ^{***} (range)	1 (14)++	13 (29) +++	32 (32)	19 (35)	0.0023

*Chronic Rhinosinusitis (CRS) without nasal polyps (CRSsNP), CRS with nasal polyps(CRSwNP),

Nonsteroidal anti-inflammatory drugs (NSAIDs)-Exacerbated Respiratory Disease (N-ERD); **Total Polyp Score (TPS); *** 20-item Sinonasal Out Come Test (SNOT-20); ⁺ datum from one participant was missing; ⁺⁺

datum from one participant was missing, ⁺⁺⁺ data from two participants were missing; n.a, not applicable

Kidane et al.

575 8. FIGURE LEGENDS

576 Figure 1: Allergic sensitization, nasal and serum type 2 cytokine levels in patient

- 577 cohorts. (A) Heat map representing specific IgE levels to selected respiratory allergens in
- sera of allergic (A, n=12) and non-allergic subjects (NA, n=12). The color gradient from
- 579 white to red represents increasing quantities of allergen-specific IgE antibodies (kUA/L). (B,
- 580 C) Log values of selected type 2 cytokines (y-axis, pg/ml) in (B) nasal secretion and (C) sera
- of allergic (black rhombus, n=12) and non-allergic (white rhombus n=12) subjects showing
- no significant differences using Mann-Whitney U test (p>0.05). Lines represent the median
- with a 95% confidence interval and the standard error of the median.

Figure 2: Elevated levels of type 2 cytokines in nasal secretions but not serum of
patients suffering from chronic rhinosinusitis (CRS) with nasal polyps (wNP) and from

- 586 nonsteroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-
- **ERD).** (A, B) Cytokine heat map and dendrogram of hierarchical clustering analysis of
- expression levels of 33 cytokines in (A) nasal secretion and (B) serum of Controls (n=6),
- 589 CRS without nasal polyps (CRSsNP, n=6), CRSwNP (n=6) and N-ERD (n=6). The color
- 590 gradient from blue to red represents an increasing quantity of cytokines (pg/ml). (C, D)
- 591 Levels (y-axis, log of pg/ml) of interleukin (IL)-4, IL-5, IL-9, IL-13, Chemokine (C-C Motif)
- 592 Ligand (CCL)17, Eotaxin, Eotaxin-3, IL-10, interferon (IFN)-γ and IL-17A in (C) nasal
- secretions and (D) serum in Controls (blue circle, n=6), CRSsNP (grey square, n=6),
- 594 CRSwNP (green triangle, n=6) and N-ERD (red triangle, n=6) are displayed. Lines represent
- the median with a 95% confidence interval and the standard error of the median; stars
- represent statistically significant differences using the Kruskal-Wallis test followed by $p_{\text{upp}'s}$ test (*: $p \leq 0.05$ **: $p \leq 0.01$)
- 597 Dunn's test (*: $p \le 0.05$, **: $p \le 0.01$).

598 Figure 3: Mass cytometry analysis of peripheral blood mononuclear cells (PBMCs) in 599 control, chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP), CRS with nasal 600 polyps (CRSwNP) and Nonsteroidal anti-inflammatory drugs (NSAIDs)-Exacerbated 601 **Respiratory Disease (N-ERD) patients.** (A) An optimized t-distributed stochastic neighbour 602 embedding (opt-SNE) map representing a consensus staining pattern and intensity levels of 603 key markers employed in mass cytometry, specifically, the markers CD3, CD4, CD8, CD11c, 604 CD19, CD56, CD161, HLA-DR, and TCR $\gamma\delta$ depicted in a concatenated file. The color 605 gradient from blue to red represents an increasing intensity of the metals tagged to the 606 specific antibodies. (B) Heat map and dendrogram of hierarchical clustering analysis 607 displaying the expression levels/metal intensities of selected markers across individual 608 immune cell types. (C) A consensus overlay of FlowSOM metaclusters on an opt-SNE map 609 of concatenated files and (D) bar chart graph of individual patients displaying major cell 610 populations characterized after FlowSOM analysis. Major immune cell types namely Natural 611 Killer (NK) Cells, Natural Killer T (NKT), Mucosal-associated invariant T (MAIT) Cells, 612 CD4+ T Cells (CD4 T), regulatory T cells (T-reg), CD8+ T Cells (CD8 T), Gamma-Delta T 613 Cells ($\gamma \delta$ T), Memory B Cells (Memory B), Naive B cells (Naive B), Plasmablasts 614 (Plasmas), Monocytes, Myeloid Dendritic Cells (mDCs), Plasmacytoid Dendritic Cells 615 (pDCs) were identified in all four patient groups: controls (n=6), chronic rhinosinusitis with 616 (CRSwNP, n=6) and without (CRSsNP, n=4) nasal polyps and non-steroidal anti-617 inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD, n=6). (E) Th2a

subset of the CD4+ T cells, manually gated (upper left panel) using marker expression

Kidane et al.

patterns shown on a heat map (upper right panel). Percentage Th2a cells (y-axis) of total
PBMCs in allergic (lower left panel, *n*=10) versus non-allergic (lower left panel, *n*=12) and in
disease groups (lower right panel). Box plots show the range with medians as horizontal lines

- and whiskers indicating minimum and maximum values. Stars represent statistically
- 623 significant differences between allergic and non-allergic groups using Mann-Whitney U test
- 624 (*: $p \le 0.05$) whereas the Kruskal-Wallis test followed by Dunn's test in disease groups
- 625 showed no significant difference (p>0.05).

Figure 4: In-detail B cell subset identification using FlowSOM. (A) B cell FlowSOM

- 627 clusters (left panel, outlined in red lines) were merged into one population and subjected to
- 628 further sub-clustering using FlowSOM analysis (right panel) into ten subtypes of B cells,
- labelled B1 to B10. (B) A consensus heatmap of the raw values of median metal intensity
- 630 (MMI) of selected markers in B1 to B10, the colour gradient from black to red represents an
- 631 increasing expression/intensity of the markers in the concatenated file. (C-F) Comparison of
- 632 percentage (y-axis) of respective B cell sub-clusters (B1-B10) of total B cells in (C, E)
- 633 Disease conditions (controls, blue, n=6; CRS without polyps (CRSsNP), grey, n=6; CRS with
- nasal polyps (CRSwNP), green, *n*=6) and Non-steroidal anti-inflammatory drug (NSAID)-
- exacerbated respiratory disease (N-ERD, n=6, red)) and (D, F) allergic conditions (allergic,
- black-white pattern, n=10; non-allergic, white, n=12). Box plots show the range with medians
- as horizontal lines and whiskers indicating minimum and maximum values. Stars represent
- 638 statistically significant differences between groups using Kruskal-Wallis test (C, E) followed
- by Dunn's test (*: $p \le 0.05$) and (D, F) using the Mann Whitney U test (*: $p \le 0.05$).
- 640 Figure 5: CD45RA, CXCR5 and CD49d expression levels in B cell subtypes. (A-C)
- 641 Median metal intensity (MMI, y-axis) in B cell sub-clusters B1-B5 (left panels) and B6 to
- B10 (right panels) of (A) CD45RA, (B) CXCR5 and (C) CD49d in controls (blue, n=6),
- 643 chronic rhinosinusitis without (CRSsNP, grey, n=6) and with (CRSwNP, green, n=4) nasal
- 644 polyps and in patients with non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated
- 645 respiratory disease (N-ERD, red, *n*=6). Stars represent statistically significant differences
- between groups using Kruskal-Wallis test followed by Dunn's test (*: $p \le 0.05$).

647 Figure 6: Characterization of early-stage (ES) and late-stage (LS) Natural killer cells

- 648 (NKs). (A) A consensus optimized t-distributed stochastic neighbour embedding (opt-SNE)
- map showing ES and LS NK cells. (B) A consensus heatmap of the raw median metal
- 650 intensity (MMI) values of selected markers characterizing NK cell subsets. The color
- 651 gradient from black to bed represents an increasing expression/intensity of the markers. (C,
- D) Percentage of NK cell subsets of total cells (y-axis) in (C) disease groups (Controls, blue,
- 653 n=6; chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP), grey, n=6; CRS with
- 654 nasal polyps (CRSwNP), green, *n*=4; non-steroidal anti-inflammatory drugs (NSAIDs)-
- exacerbated respiratory disease (N-ERD), red, n=6) and in (D) allergic (black-white pattern,
- 656 n=10) and non-allergic (white, n=12) patients. (E, F) Median metal intensity (MMI) of (E)
- 657 CD45RA and (F) CD56 in NK cell subtypes in disease groups (as described in C). Box plots
- show the range with medians as horizontal lines and whiskers indicating minimum and
- 659 maximum values. Stars represent statistically significant differences between groups using $K_{\rm rescaled}$ Wellie test (C. E) following $K_{\rm rescaled}$ (C. E) following
- 660 Kruskal-Wallis test (C, E) followed by Dunn's test (*: $p \le 0.05$) and (D) using Mann-Whitney
- 661 U test (*: $p \le 0.05$).



Figure 1



Figure 2



opt-SNE_1





Figure 4



Figure 5





Figure 6